-transparent.png){kind=logo}
Monoiodotyrosine is a tyrosine hydroxylase inhibitor. Ingestion of one gram monoiodotyrosine caused a 10,000-fold increase of serum monoiodotyrosine from basal levels of 0.69 +/- 0.20 nmol/l to a peak of 10.6 +/- 1.7 mumol/l in women and 7.1 +/- 2.3 mumol/l in men 30 min later, and the t1/2 was 45 min. Monoiodotyrosine stimulated PRL to a peak of 170 +/- 51 micrograms/l in women and 90 +/- 6 micrograms/l in men 30 min after the monoiodotyrosine peak, or 60 min after the ingestion. Other anterior pituitary hormones were unchanged. Dopamine infusion or L-dopa pretreatment attenuated the monoiodotyrosine effect. TRH exaggerated the PRL peak, and chlorpromazine did not increase but prolonged the hyperprolactinemia. These results suggest that dopamine synthesis inhibition may be the mechanism of PRL stimulation.
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
January 1972,
Neuroendocrinology,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
May 2001,
Clinical physiology (Oxford, England),
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
October 2011,
Molecular autism,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
September 1996,
The Journal of pharmacology and experimental therapeutics,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
January 1987,
Drugs under experimental and clinical research,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
November 1981,
British journal of clinical pharmacology,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
July 1980,
Acta endocrinologica,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
January 1961,
Postgraduate medicine,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
November 1965,
Horumon to rinsho. Clinical endocrinology,
S A Tan, and
J E Lewis, and
L S Berk, and
R B Wilcox
May 1978,
The Journal of clinical endocrinology and metabolism,
